Table 1.
Baseline characteristics of organ recipients and donors
| ATG | Daclizumab | |
|---|---|---|
| Characteristics | n = 113 | n = 114 |
| Males, n (%) | 52 (46.0) | 59 (51.8) |
| Age, yr (mean ± SD) | 45.4 ± 10.3 | 46.9 ± 9.0 |
| Cause of ESRD, n (%) | ||
| Glomerulonephritis | 51 (45.2) | 45 (39.4) |
| Uropathy | 11 (9.7) | 15 (13.2) |
| Autosomal dominant polycystic kidney disease | 10 (8.9) | 10 (8.8) |
| Diabetes | 4 (3.5) | 2 (1.7) |
| Other | 26 (23.0) | 25 (21.9) |
| Unknown | 11 (9.7) | 17 (15.0) |
| Number of HLA mismatches | ||
| HLA A | 0.9 ± 0.7 | 0.9 ± 0.7 |
| HLA B | 1.1 ± 0.7 | 1.1 ± 0.8 |
| HLA DR | 0.9 ± 0.7 | 0.9 ± 0.8 |
| First graft, n (%): | 30 (26.5%) | 34 (29.8%) |
| Current PRA (mean ± SD, %) | 35 ± 32 | 39 ± 33 |
| Peak PRA (mean ± SD, %) | 77 ± 20 | 79 ± 20 |
| Second graft, n (%): | 59 (52.2%) | 58 (50.9%) |
| Current PRA (mean ± SD, %) | 35 ± 29 | 39 ± 31 |
| Peak PRA (mean ± SD, %) | 69 ± 23 | 75 ± 18 |
| Third and fourth graft, n (%): | 24 (21.2%) | 22 (19.3%) |
| Current PRA (mean ± SD, %) | 26 ± 30 | 27 ± 31 |
| Peak PRA (mean ± SD, %) | 60 ± 30 | 61 ± 27 |
| All patients | n = 113 | n = 114 |
| Current PRA (mean ± SD, %) | 33 ± 30 | 37 ± 32 |
| Peak PRA (mean ± SD, %) | 69 ± 25 | 74 ± 22 |
| % with PRA >80% | 8.8% | 11.4% |
| Cold ischemia time, h (mean ± SD) | 24.0 ± 7.9 | 22.7 ± 6.8 |
| Donor | ||
| Males, n (%) | 76 (67.3) | 65 (57.0) |
| Age, yr (mean ± SD) | 44.3 ± 13.8 | 44.6 ± 14.8 |
| Death from stroke, n (%) | 56 (49.6) | 46 (40.4) |
| Cytomegalovirus serologic status, n (%) | ||
| D+R+ | 37 (32.7) | 45 (39.5) |
| D+R− | 16 (14.2) | 12 (10.5) |
| D−R+ | 46 (40.7) | 42 (36.8) |
| D−R− | 14 (12.4) | 15 (13.2) |